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Abstract
HIV controllers (HICs), rare HIV-1 infected individuals able to control viral replication without
antiretroviral therapy, are characterized by an efficient polyfunctional and cytolytic HIV-spe-
cific CD8+ T cell response. The mechanisms underlying the induction and maintenance of
such response in many HICs despite controlled viremia are not clear. Dendritic cells play a
crucial role in the generation and reactivation of T cell responses but scarce information is
available on those cells in HICs. We found that monocyte derived dendritic cells (MDDCs)
from HICs are less permissive to HIV-1 infection than cells from healthy donors. In contrast
MDDCs from HICs are particularly efficient at capturing HIV-1 particles when compared to
cells from healthy donors or HIV-1 patients with suppressed viral load on antiretroviral treat-
ment. MDDCs from HICs expressed on their surface high levels of syndecan-3, DC-SIGN
and MMR, which could cooperate to facilitate HIV-1 capture. The combination of low sus-
ceptibility to HIV-1 infection but enhanced capacity to capture particles might allow MDDCs
from HICs to preserve their function from the deleterious effect of infection while facilitating
induction of HIV-specific CD8+ T cells by cross-presentation in a context of low viremia.
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Introduction
HIV controllers (HIC), rare HIV-1 infected individuals, are able to maintain undetectable vire-
mia for several years without any therapeutic intervention [1, 2]. Several studies reported the
major role of CD8+ T cell response in viral containment in these patients. Indeed, despite low
viremia, HICs have high frequency of HIV-specific CD8+ T cells [3, 4] displaying a more poly-
functional response to HIV than cells from patients non-controlling infection [5, 6]. Moreover,
CD8+ T cells from HIC exhibit a striking capacity to eliminate autologous infected CD4+ T
cells [4, 7], which is likely related to their capacity to rapidly upregulate cytotoxic granules [8,
9]. The presence of “protective” HLA alleles, such as HLA-B57 or B27, which are overrepre-
sented in HIC [4, 10, 11], may contribute to the priming of such effective HIV-specific CD8+ T
cell responses by efficiently presenting HIV antigens and selecting high avidity CTL clonotypes
[12, 13]. However, not all HLA-B57 individuals are able to develop similar HIV-specific CD8
+ T cell responses and many HIC with robust CD8+ T cell responses do not carry protective
HLA alleles [3, 13, 14]. Therefore, understanding the mechanisms underlying the generation
and the maintenance of such efficient CD8+ T cell response is of outmost interest, as this char-
acterization might give insights for new therapeutic strategies to achieve control of infection in
the absence of antiretroviral treatment.
Myeloid dendritic cells (DC) play a central role in the induction of virus-specific CD8+ T
cell responses, since they are the most potent antigen presenting cells and unique for their
capacity to activate naïve T cells. DCs activate CD8+ T cells by presenting antigen bound by
major histocompatibility complex molecules class-I (MHC-I). Virus-infected DCs can use
endogenously synthesized viral proteins stemming from viral replication as antigens for pre-
sentation on MHC-I and this process is commonly called “classic or direct presentation” [15].
Whereas, non-infected DCs need to actively engulf exogenous viral antigens for presenting
them to CD8+ T cells by “cross-presentation” process [16].
DCs are susceptible to HIV-1 infection [17] although less permissive compared to activated
CD4+ T cells. This restriction is related, in part, to the antiviral activity of SAMHD-1 that
degrades the cellular dNTP pool [18, 19], crucial for HIV reverse transcription, and viral nucleic
acids [20]. Restriction of HIV-1 replication in DCs prevents sensing of the virus [18, 21]. Indeed,
when restriction is relieved by delivery of Vpx which induce SAMHD-1 degradation, there is bet-
ter sensing of HIV-1 marked by induction of IFN-I response, up regulation of cell surface CD80
and CD86 costimulatory molecules that provide an efficient stimulation of CD4+ and CD8+ T
cells [21]. We and others have demonstrated that CD4+ T cells and macrophages from HIC are
less susceptible to HIV-1 infection than cells from other patients [22–24]. However it is unknown
whether this resistance to HIV-1 also extends to HIC DCs. An analysis of the interactions
between HIC DCs and HIV-1 appears thus crucial for better understanding the mechanisms
underlying the priming and maintenance of the efficient HIV-specific CD8+ T cell response in
HIC. In this context, we explored the susceptibility of HIC DCs to HIV-1 infection in vitro as
well as their capacity to capture HIV-1 virions. Our findings indicate that DCs fromHIC are rela-
tively resistant to HIV-1 infection, which could preserve their function. In addition, DCs from
HICs showed high capacity to uptake HIV-1 particles which might facilitate induction of HIV-
specific CD8+ T cells by cross-presentation in the context of low viremia.
Results
MDDCs from HIC have low susceptibility to HIV-1 infection
We previously demonstrated that CD4+ T cells and macrophages from HIC are relatively resis-
tant to HIV-1 infection [22]. We wondered whether the same resistance to infection could be
HIV Capture and Infection in Dendritic Cells from HIV Controllers
PLOS ONE | DOI:10.1371/journal.pone.0160251 August 9, 2016 2 / 13
found in DCs. Limited sample availability did not allow us to conduct functional experiments
with circulating DCs. We therefore investigated the susceptibility to HIV-1 infection using
monocytes derived dendritic cells (MDDC) from HICs (n = 42) and HDs (n = 34). MDDC
were infected with HIV-1 BaL and cultured for 20 days post-infection. Viral production was
monitored every 3–4 days. MDDCs from HDs sustained viral replication with peak viral pro-
duction at days 13–15 post-infection (see Fig 1A for three representative experiments and Fig
1B for group medians). In contrast, viral replication was severely impaired in MDDCs from
HICs at all time points analyzed (Fig 1B). Overall, the peak of viral replication was lower in
MDDCs from HIC than from HD (p = 0.0004) (Fig 1C), demonstrating that HIV-1 replicates
less efficiently in cells from HICs.
We wondered whether the reduced HIV-1 susceptibility of MDDCs from HICs to infection
could be related to a stronger IFN-response in HICs’MDDCs upon HIV-1 infection [21]. We
measured the bioactive IFN-α in culture supernatants of MDDCs from 19 HICs and 15 HDs at
4h, 24h, 5, 7, 10 and 13 days after HIV-1 challenge. We found no difference between HIC and
Fig 1. Susceptibility of MDDCs from HIC and HD to HIV-1 infection. (A) Kinetic of HIV-1 BaL replication in MDDC from three HIC (red) and three HD
(blue) in three independent and representative examples. p24 production in culture supernatants is represented as the mean ± SD of 3 independent cultures
for each individual. (B) Kinetic of HIV-1 Bal production in supernatant of HIC and HDMDDC’s. p24 production in culture supernatants is represented as the
mean ± IQR of 34 HD and 42 HIC. (* p<0.05; ** p<0.01; *** p<0.001) (C) Viral production at peak of infection in culture supernatants. Symbols represent
the average (n = 3 independent experiments) of p24 values detected in culture supernatants for each subject (HD n = 34 and HIC n = 42). Horizontal lines
represent median ± interquartile values for each group.
doi:10.1371/journal.pone.0160251.g001
HIV Capture and Infection in Dendritic Cells from HIV Controllers
PLOS ONE | DOI:10.1371/journal.pone.0160251 August 9, 2016 3 / 13
HD cells in the levels of IFN-α production. In fact, IFN-α was not detected in most samples
and at most time points, with the exception of 3 HDs (EFS 171, EFS 300 and EFS 377, with 4.3,
5.4 and 16.5 IFN-α IU/ml, respectively) and one HIC (56011, 24 IFN-α IU/ml) at the peak of
viral replication (S1 Table). Viral replication in the cells from these subjects was not different
from what was observed with cells from other subjects in their groups. Overall, our results sug-
gest that low HIV-1 susceptibility of HICs’MDDCs is not related to an enhanced production
of IFN-α by these cells upon contact with HIV-1.
MDDCs from HICs have an enhanced capacity to capture HIV-1
particles
The reduced susceptibility of MDDCs from HICs to HIV-1 infection suggests that the superior
HIV-specific CD8+ T cell responses found in HICs are not likely due to direct antigen presen-
tation by their DCs. We wondered whether other mechanisms could help to an efficient pre-
sentation of HIV antigens to CD8+ T cells in the context of low productive infection. We
therefore analyzed the capacity of MDDCs from HICs to capture free viral particles when com-
pared to cells from HDs and cARTs.
MDDCs were incubated with HIV-1 BaL during 4h at 37°C. After extensive washing to
get rid of unbound viral particles, cells were lysed and used to quantify the level of HIV-1
p24 antigens associated with the cells. Our results showed higher levels of p24 associated
with MDDCs from HICs than with MDDCs from HDs (p = 0.001) or cART patients
(p = 0.0004), the latter cells being the ones with the lowest levels of associated p24 (p = 0.047)
(Fig 2). Interestingly, no correlation was found between the levels of HIV-1 capture and the
susceptibility to HIV-1 infection of MDDCs from either HICs or HDs (S1 Fig). These results
suggest that MDDCs from HICs captured HIV-1 particles more efficiently than cells from
HDs and cARTs.
Fig 2. Capture of HIV-1 Bal by MDDC.Cell-associated p24 levels 4h after exposure to virus. Symbols
represent the average p24 levels (n = 3 independent experiments) for each individual (HDs n = 47, HICs
n = 44 and cARTs n = 14). Horizontal lines represent median ± interquartile values for each group.
doi:10.1371/journal.pone.0160251.g002
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MDDCs from HICs, HDs and cARTs have similar general capacities to
capture and degrade antigens
We wondered whether the higher capacity of MDDCs from HIC to capture HIV-1 particles
was related to a higher general capacity of their cells to capture and process antigens. We used
Alexa 488-conjugated dextrans (10 000 MW) and DQ-ovalbumin to evaluate the capacity of
MDDCs to uptake antigens by endocytosis through mannose receptors or by macropinocyto-
sis. The DQ-Ovalbumin is a self-quenched BODIPY FL conjugate of albumin that exhibits
bright fluorescence upon endo-lysosomal proteolysis, which also allowed us to evaluate the
capacity of MDDCs to route antigens towards degradative compartments.
Antigens were added to cell cultures and their uptake by MDDCs was measured 4h later by
flow cytometry. As illustrated in Fig 3A, no differences were observed in the uptake capacity of
MDDCs from HICs, HDs and cARTs. Likewise, MDDCs from the three groups of individuals
Fig 3. Antigen uptake and degradation by MDDC. Dextran uptake (A) and ovalbumine uptake and degradation (B) by MDDC from HDs,
HICs and cARTs. Top panels are examples with cells from three representative individuals of each group (light grey is the negative control,
blue is one HD, red one HIC and dark grey is a cART). Bottom panels present the summary of all the experiments performed. Each circle
represents one individual, and the horizontal lines represent the median ± interquartile values for each group (HD n = 31, HIC n = 23 and
cART n = 16).
doi:10.1371/journal.pone.0160251.g003
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exhibited similar levels of ovalbumin uptake and degradation (Fig 3B). Therefore MDDCs
from HICs appear to have a similar intrinsic capacity to capture and process antigens when
compared to cells from HDs and cARTs.
C-type lectin receptors and syndecan-3 are more expressed on the
surface of HICs’MDDCs
Our results suggest that the enhanced capacity of MDDCs from HICs to capture HIV-1 may be
related to specific interaction of MDDCs with the HIV-1 particles. We therefore assessed the
surface expression on MDDC from HICs, HDs and cARTs of different molecules that have
been associated with HIV-1 capture. No difference was found in the expression of CD4, CCR5
or CXCR4 on MDDC from HICs, HDs and cARTs (Fig 4A). The expression of the Fcγ recep-
tors (CD16, CD32 and CD64) or CD91 was not higher in the cells from HICs (S2 Fig). In con-
trast, we found that MDDCs from HICs expressed higher levels of MMR (p = 0.021) and
Fig 4. Expression of surface receptors on MDDC. (A) Expression levels of CD4, CXCR4 and CCR5 on MDDC from HDs (n = 11), HICs (n = 12) and
cARTs (n = 18). (B) Idem for DC-SIGN, MMR and Syndecan-3 (HDs n = 19, HICs n = 14 and cARTs (n = 13). Each symbol represents one individual and
horizontal lines represent the median ± interquartile for each group. * represents p<0.05; ** represents p<0.01. (C) Correlations between the levels of p24
captured by MDDC and their surface expression of MMR, DC-SIGN and Syndecan-3. Each symbol represents data obtained with cells from one patients
(n = 29).
doi:10.1371/journal.pone.0160251.g004
HIV Capture and Infection in Dendritic Cells from HIV Controllers
PLOS ONE | DOI:10.1371/journal.pone.0160251 August 9, 2016 6 / 13
Syndecan-3 (p = 0.006) compared to cells from HDs (Fig 4B), although not significantly higher
than MDDCs from cARTs. In addition, the frequency of MDDCs with detectable levels of
DC-SIGN was higher in MDDCs from HICs than in MDDCs from HDs (p = 0.035) or cARTs
(p = 0.003). We found a correlation between the surface expression of MMR and the amount
of p24 that the MDDCs captured in 29 subjects in whom both parameters were analyzed simul-
taneously (Fig 4C). We also found a tendency between the expression of syndecan-3 and the
levels of p24. Overall, our results suggest that high expression of MMR, syndecan3 and
DC-SIGN on the surface of MDDCs from HICs could synergize and cooperate with the HIV-1
receptors CD4 and CCR5 to efficiently capture HIV-1 particles.
Discussion
In the present study we found that MDDC from HICs are less susceptible to HIV-1 infection
than cells from healthy donors. In addition, our results show for the first time that MDDC
from HICs capture greater amounts of HIV-1 than do MDDC from HD and cART patients.
The reduced susceptibility of MDDC from HICs to HIV-1 infection is in agreement with
previous studies showing a reduced permissiveness to HIV-1 of CD4+ T cells and macrophages
from the same patients [22–24]. Our results are consistent with a recent report of low infection
level of primary DCs from HIC compared to cells from healthy donors [25]. Our findings sug-
gest that an intrinsic resistance to HIV-1 infection is generalized to different cell subsets from
HICs, strengthening the hypothesis that this feature contributes to the viral control in these
individuals [22]. It has been recently proposed that an efficient sensing of HIV-1 by target cells
could trigger IFN-I responses which would contribute to increase viral restriction in the cells
and, in the case of DCs, enhance their capacity to activate HIV-specific T cell responses [26].
Martin-Gayo and colleagues recently found higher induction of type I IFN and interferon stim-
ulated genes in primary DCs from HIC after HIV-1 infection [25]. We did not find detectable
levels of IFN-α produced by cells from either HICs and HDs after infection, in accordance with
the literature [21, 27]. Although it is still unclear whether the same mechanism(s) of restriction
are responsible for relative resistance to HIV-1 infection of different cell types from HICs, we
did not find evidences of increased IFN-α activity either in previous studies on CD4+ T cells
and macrophages from HICs ([22] and not shown). The discrepancy between our results and
the results by Martin-Gayo and colleagues could be due to the difference in the cell models ana-
lyzed (MDDC vs circulating BDCA1+ DC) as well as the way to measure IFN-I response
(quantification of IFN-I in supernatants in our study vs intracellular mRNA levels).
Infection of DCs by HIV-1 causes different disturbances on these cells compromising their
functions, including their capacity to stimulate CD8+ T cells [28, 29]. Based on our results we
can therefore speculate that resistance of MDDC from HIC to HIV-1 infection may preserve
their function and capacity to induce efficient CD8+ T cell responses. DCs are able to present
HIV-1 antigens to CD8+ T cells either by processing intracellular protein stemming from HIV
replication or by uptake of HIV-1 antigens from extracellular media. Interestingly, while
MDDCs from cART patients seemed to capture HIV-1 particles less efficiently than cells from
healthy donors, the MDDCs from HICs showed an enhanced capacity to bind HIV-1 when
compared to cells from the two other groups of individuals. This efficient capture of HIV-1 by
MDDCs from HICs is not explained by increased expression of CD4 or CCR5 on the cell sur-
face. In contrast, we observed high expression of MMR, Syndecan-3 and, in particular,
DC-SIGN on HICMDDCs. These receptors are known to interact with carbohydrates on the
surface of gp120 enhancing and stabilizing the capture of HIV particles by DCs [30–32]. The
high expression of these receptors was not associated with a higher capacity of MDDCs from
HICs to capture dextrans or ovalbumine. Although MMR-independent capture of these
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molecules may contribute to this lack of difference, these results suggest that MDDCs from
HICs do not have a general higher capacity to capture and process antigens. High levels of
MMR, DC-SIGN and Syndecan-3 may however act synergistically with other viral receptors
on the surface of MDDCs such as CD4 and CCR5 to enhance HIV-1 capture, although we did
not have enough cells to directly evaluate this possibility.
The route of antigen uptake, dictate the pathway for antigen processing and presentation.
Interestingly, the involvement of both MMR and DC-SIGN in the capture of exogenous anti-
gens promotes the cross-presentation process [33–37]. Thus, it is tempting to speculate that
the higher expression of MMR, DC-SIGN and syndecan-3 on MDDCs from HICs might coop-
erate for HIV-1 uptake and could favor cross-presentation of HIV-1 antigens to CD8+ T cells.
Increased binding of HIV-1 particle through MMR or DC-SIGN might enhance transmission
of infection to CD4+ T cells [38, 39], however this effect might be limited in the case of HIV
controllers due to the relative resistance of their CD4+ T cells to HIV-1 infection [22, 23]. The
properties of DCs from HICs might also be relevant to the priming and activation of their
HIV-specific CD4+ T cell responses, which have been shown to possess a highly efficient effec-
tor phenotype able to respond to limit amounts of antigens [40, 41]. Combined, the properties
of DCs from HICs might protect them from HIV-1 infection, thereby preserving their func-
tionality, while favoring the cross-priming of HIV-specific CD8+ T cell responses in a context
of low antigen availability.
Materials and Methods
Subjects
HICs were enrolled from the ANRS CO21 cohort and were defined as patients infected
by HIV-1 for  5 years who never received antiretroviral treatment and whose last 5 con-
secutive plasma HIV RNA values were < 400 copies/mL. HIV-infected patients on an-
tiretroviral therapy with viral load < 50 RNA copies/mL for  6 months (cART) were
recruited among patients followed at Hôpital Foch, Hôpital Européen Georges-Pompidou
and Hôpital Saint-Louis in France. A summary of the characteristics of the HIV-1 patients
included in the study can be found in the S2 Table. Blood samples from healthy HIV-sero-
negative donors (HD), were obtained from the Establissement Français du Sang (EFS) and
Institut Pasteur plate-form Investigation Clinique et Accès aux Ressources Biologiques
(ICAReB).
Ethics Statement
All enrolled patients gave written informed consent to participate in the study. The CO21 HIV
controller cohort is sponsored by the French National Agency for Research on AIDS and Viral
Hepatitis (ANRS). The C021 CODEX cohort and this substudy protocol were approved by the
ethics review committee of Ile de France VII and the institutional review board of Institut
Pasteur.
Generation of monocyte derived dendritic cells (MDDC)
Peripheral blood mononuclear cells (PBMC) were isolated from fresh whole blood by density
gradient in lymphocyte separation medium (Eurobio, Abcys). Red blood cells were lysed by
hypotonic shock. Monocytes (CD14+) were purified from PBMC by positive selection with
antibody magnetic beads in a Robosep instrument (Stem cell Technology). Monocytes were
differentiated into dendritic cells in presence of GM-CSF (1000 IU/ml) and IL-4 (1000 IU/ml)
(R&D Systems) during 6–7 days.
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Infection of MDDC
Immature MDDC (105) were pulsed in triplicate with HIV-1 BaL (10−1,3 MOI) during 4h at
37°C. The cells were then washed twice and cultured for 20 days. Every 3–4 days, culture super-
natants were recovered and replenished with fresh medium. Viral replication was monitored in
supernatants by p24 Elisa (Zeptometrix, Gentaur, France).
HIV-1 capture
MDDC (105) were pulsed in triplicate with HIV-1 BaL (2 ng of p24/105 cells) in 100 μl of
medium for 4 h at 37°C without spinoculation. Cells were then washed three times to eliminate
free HIV particles and lysed. Cell-associated HIV-1 was quantified by Elisa p24 (Zeptometrix,
Gentaur,France).
Quantification of bioactive IFN-α
IFN-α activity in culture supernatants of infected DCs was determined, at different time points
after infection, using an ultrasensitive functional assay based on protection of Madin-Darby
bovine kidney (MDBK) cells against the cytolytic effect of vesicular stomatitis virus [42]. The
titers were expressed in international units based on the reference standard for human IFN-
alpha (G-023-901-527; NIH, Bethesda, MD).The test measures all subtypes of human IFN-α.
Study of antigen uptake and degradation by MDDCs
To analyze the capacity of MDDCs to capture different antigens we measured the uptake of
Alexa 488-labelled dextran and DQ ovalbumin. MDDCs (105) were pulsed with 5 μg of Dex-
tran-Alexa fluor 488 (Life Technologie) or DQ-Ovalbumine (Life Technologie) during 4 h at
37°C or 4°C. Cells were washed twice, stained during 15 min at 4°C with anti-HLA-DR-ECD
(Beckman Coulter) and anti-CD11c-V450 (BD Biosciences) antibodies and then fixed with 2%
of paraformaldehyde. Cells were analyzed with a LSR II flow cytometer (Becton Dickinson).
Cells incubated at 4°C were used as negative control.
Expression of receptors on the surface of MDDCs
MDDC were incubated 15 min at RT with CD11c-V450 (clone mP9, BD), HLA-DR-ECD
(clone Immu-357, BC) and with different panel of antibodies to assess the expression level of
different receptors. Panel I: CD4-FITC (clone L120, BD), CCR5-APC (clone 3A9, BD),
CXCR4-PE (clone 12G5, BD); Panel II: MMR-FITC (clone19.2, BD), DC-SIGN-PerCp (clone,
R&D), CD91 (clone A2MR-α2, BD), Syndecan 3 PerCp Cy5.5 (clone MI15, BD); and Panel III:
CD16-APC (Clone B73.1, BD), CD32-PE(Clone 3D3, BD), CD64-FITC (Clone 10.1, BD).
After staining, cells were washed twice and resuspended in PBS containing 2% of paraformal-
dehyde and 1% of fetal calf serum. MDDC were confirmed as HLA-DR and CD11C positive
cells. Data were acquired on a LSR II cytometer and analysed using DIVA software (both from
BD Biosystems).
Statistical analyses
Data were described by medians and interquartile ranges (IQR) for continuous variables Non-
parametric ANOVA or Mann-Whitney tests were used to compare datasets between groups.
The Spearman’s non parametric correlation was used to estimate the association of two contin-
uous variables of interest.
All statistical analyses were done with GraphPad Prism 5.03 software (GraphPad software,
La Jolla, USA). In 2-tailed tests, P values of 0.05 or lower were considered significant.
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